Pfizer-Medivation cash deal is hard to justify: Analyst

Pfizer investors should be concerned about the high premium, while Medivation investors should celebrate, says RBC Capital Markets' Simos Simeonidis.

from Mergers and Acquisitions http://ift.tt/2bd36it